Clinical Liver Disease

Hepatocellular carcinoma is the most rapidly increasing cause of cancer mortality with poor prognosis in the United States. Molecular biomarkers are emerging as a way to enable effective, personalized patient management with limited medical resources. Dr. Hoshida reviews molecular risk factors of HCC development, molecular subclasses of aggressive HCC tumor, and the need for clinical translation of molecular indicators of HCC risk.